Why ankle cartilage injuries are so easy to miss

An ankle sprain that seems to have healed but never quite does — residual aching on uneven ground, intermittent swelling after a run, a vague sense that the joint isn't quite right — is one of the more common presentations in a cartilage clinic. In many of these cases, the underlying problem is an osteochondral lesion of the talus (OLT): damage to the cartilage surface, and sometimes the bone beneath it, that occurred at the time of the original injury.

The condition is more common than most patients expect. Up to 50% of ankle sprains and over 70% of ankle fractures are associated with talar cartilage damage — yet none of it shows on a standard X-ray. Plain radiographs reveal bone, not cartilage, which is why a normal X-ray report does not rule out a significant lesion. MRI is the investigation that changes the picture: it identifies the size, depth, and location of the defect, and determines whether the surrounding cartilage is healthy enough to make a scaffold-based approach viable.

OLT predominantly affects active adults aged 20–40, and the window between injury and effective intervention matters. A well-contained focal defect behaves very differently from widespread joint degeneration — and the distinction shapes what treatment options are appropriate.

What ChondroFiller is and how it supports repair

ChondroFiller Liquid is a CE-marked Class III medical device — an injectable collagen scaffold manufactured from rat-tail tendon using a non-enzymatic, weak-acid extraction process. That extraction method matters: it preserves the telopeptide end-regions of the collagen molecule intact, maintaining the protein's capacity for physiological cross-linking and fibril self-assembly. Remove those regions enzymatically, as conventional industrial routes do, and the structural integrity of the final scaffold is compromised.

Once injected into the joint under ultrasound guidance, the liquid self-gels within minutes, conforming to the defect space. What follows is acellular matrix-induced chondrogenesis: the scaffold itself contains no cells, but its architecture acts as a chemotactic signal, drawing the patient's own mesenchymal stem cells in from the surrounding synovium and subchondral bone. Those recruited cells progressively differentiate into chondrocytes and, over months, remodel the biodegrading scaffold toward hyaline-like repair tissue. ChondroFiller provides the structure; the patient's own biology does the regenerative work.

This distinguishes it clearly from hyaluronic acid, which functions as a lubricant and is cleared from the joint within weeks without contributing a structural matrix for cell recruitment. It is equally distinct from permanent synthetic gels, which remain in the joint indefinitely and cannot be biologically integrated or remodelled. ChondroFiller is designed to disappear as the body's own repair tissue takes its place — a temporary scaffold rather than a permanent implant.

How the injection is delivered to the ankle

The appointment takes place as an outpatient procedure under ultrasound guidance — no general anaesthetic, no arthroscopic access, no surgical admission. Crucially, there is no need to debride the lesion bed beforehand: ChondroFiller is introduced into a naturally fluid joint environment rather than requiring a dry, surgically prepared field. Real-time imaging confirms accurate delivery to the focal defect on the talar dome, so the scaffold reaches precisely the site where the repair process needs to begin.

This additive placement leaves the surrounding cartilage and soft-tissue structures undisturbed. Patients leave the clinic on the same day, without wound care or a theatre recovery period.

The ankle is one of three primary joints treated with ChondroFiller — alongside the knee and hip — and indications cover post-traumatic chondral and osteochondral lesions as well as osteochondritis dissecans of the talar dome. Which of those indications applies, and whether the surrounding cartilage borders are healthy enough to support scaffold-based repair, is determined by MRI assessment before the appointment is arranged.

Who is a suitable candidate for ankle ChondroFiller

The patients most likely to benefit from ankle ChondroFiller share a recognisable pattern on MRI: an isolated, focal area of cartilage loss graded III or IV, with the surrounding cartilage retaining enough structural integrity to provide a healthy border. That border matters because the injected scaffold depends on an intact perimeter — one from which the recruited repair cells can anchor and spread across the defect.

Defect size is a defining variable. Published evidence supports ChondroFiller for lesions up to 6 cm², a range meaningfully wider than what older marrow-stimulation techniques can reliably address. Patients whose damage extends broadly across the joint rather than sitting as a discrete focal lesion are better assessed for a different pathway; the scaffold approach is designed for contained defects, not diffuse global degeneration.

Age alone does not determine eligibility. The procedure carries no strict upper age limit, and older patients are not excluded by default. A patient of 60 with a well-defined talar defect and good surrounding cartilage may be an excellent candidate, while a younger patient with diffuse joint-wide degeneration may not be. The focal nature of the problem matters far more than the number of years.

Radiographic 'bone on bone' is similarly not an automatic bar. If MRI confirms the damage is focal rather than generalised, a scaffold-based approach remains on the table for assessment. Both post-traumatic osteochondral lesions and osteochondritis dissecans of the talar dome fall within the ankle indication — the relevant question is always whether a discrete defect with viable surrounding tissue is confirmed on imaging.

What MOCART imaging shows and what to expect over time

MRI after ChondroFiller uses a scoring framework called MOCART — Magnetic Resonance Observation of Cartilage Repair Tissue — which grades defect fill, surface integration, and the structural quality of regenerating tissue on a scale up to 100. It gives clinicians a standardised means of tracking what is happening inside the joint as the scaffold matures, rather than relying solely on symptom reports.

Across published ChondroFiller studies, MOCART scores fall in the range of 70–87, corresponding to good-to-excellent structural repair. Timing matters when interpreting these figures: scores improve progressively over the first twelve months as the scaffold is gradually remodelled by host tissue, so MRI taken in the early weeks after injection will typically underestimate the final structural outcome.

Ankle-specific MOCART data is not reported separately in the available literature — the 70–87 range is drawn from multi-joint evidence spanning more than 19,000 procedures over a decade, with the ankle as one of the three most frequently treated joints. The figures represent an extrapolation to the ankle rather than a finding from a dedicated talar cohort, a gap the field has yet to fill with ankle-specific controlled trial data.

The broader multi-joint evidence does, however, provide meaningful reference points. Functional scores in published studies improve by approximately 30 IKDC points in the knee and approximately 33 points on the Harris Hip Score in the hip — metrics that, though joint-specific, indicate the scale of patient-reported benefit that accompanies scaffold remodelling. That scale of improvement sits alongside a consistently clean safety profile: complication rates in the published evidence run at approximately zero. On durability, ChondroFiller's reoperation rate of approximately 3–8% compares directly with microfracture — a marrow-stimulation technique restricted to defects under 2–4 cm², producing fibrocartilage rather than hyaline-like repair tissue, and carrying reoperation rates reported at up to 41%.

Getting assessed for ChondroFiller at the ankle

A specialist cartilage assessment is the practical gateway — confirming on MRI whether a lesion is focal, whether the surrounding cartilage is intact, and whether the ankle anatomy suits an injectable scaffold approach. Without that imaging review, candidacy cannot be determined.

At London Cartilage Clinic on Harley Street, assessment includes MRI review, a candidacy evaluation, and a structured conversation about the full treatment pathway — including the twelve-month tissue-maturation timeline described above. Professor Paul Y. F. Lee, who leads the clinic's cartilage assessment and image-guided injection service, brings specific expertise in scaffold-based treatment for focal joint lesions. Patients who are not based in London may find the MSK Doctors group's Lincolnshire and Grantham sites a more convenient point of entry — the same clinical framework applies across the group.

To arrange an assessment, visit londoncartilage.com to book a consultation.